Table 2.
Characteristics of NSCLC studies included in the meta-analysis.
| Author | Year | Tumor Type | Patients | Endpoints | MVA * | Uptake Metric | Cut-Off Value | SUV Threshold | Reconstruction Algorithm | Treatment | Stage | Median Follow Up Time | Data Extraction |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ahuja et al. | 1998 | NSCLC | 155 | OS | Yes | SUVpeak (SUR) 80% of max | 10.0 | Fitted | - | Surgery, RT, CRT | I-IV | 20.9 months | HR |
| Aoki et al. | 2016 | NSCLC | 74 | LC | Yes | SUVmax, AID | 4.0 | Literature | - | SBRT | I | 24.5 months | HR |
| Borst et al. | 2005 | NSCLC | 51 | DSS, OS | No | SUVmax, SUV cont. variable | 15.0 | Median | OSEM | CRT | I-III | 17 months | KM |
| Carvalho et al. | 2013 | NSCLC | 220 | OS | No | MTV, SUVmax, SUV | 10.12 | Median | OSEM | RT, CRT | I-IIIB | 1.47 years | KM |
| Cerfolio et al. | 2005 | NSCLC | 315 | OS, DFS | Yes | SUVmax | 10.0 | Median | Iterative | Surgery +/− CRT | I-IV | 26 months | HR |
| Chen et al. | 2012 | NSCLC | 105 | PFS, OS | Yes | TLG, MTV, SUVmax | 15.0 | Fitted | OSEM | Surgery, CT, RT or CRT | I-IV | 3.1 years | HR |
| Clarke et al. | 2012 | NSCLC | 82 | OS, RFS, DFS, CSS, RR, LR, DM | No | SUVmax | 4.75 | Median | - | SBRT | I | 2 years | KM |
| Hamamoto et al. | 2011 | NSCLC | 26 | LFF | No | SUVmax | 5.0 | Fitted | - | SBRT | I | 21 months | KM |
| Hofheinz et al. | 2016 | NSCLC | 31 | PFS, OS | No | SUV, SURtc, Kslope | 7.6 | Fitted | PSF + TOF | CRT and/or surgery | T1-4N0-3M0 | - | HR |
| Horne et al. | 2014 | NSCLC | 95 | LC, PFS, OS | Yes | SUVmax | 5.0 | Literature | - | SBRT | IA-IB | 16.33 months | HR |
| Huyn et al. | 2015 | NSCLC | 161 | DFS, OS | Yes | SUVmax, MTV | 14.0 | Fitted | OSEM | Surgery +/− CT and/or RT | IIIA-N2 | 20 months | HR |
| Imamura et al. | 2011 | NSCLC | 62 | OS, PFS | No | SUVmax | 6.0 | Median | 3D-RAMLA | CT or CRT | IIB-IV | 464 days | KM |
| Jiang et al. | 2018 | NSCLC | 151 | OS | No | SUVmax | 13.8 | Median | - | CRT, RT, CT | I-IV | 10 years | HR |
| Kohutek et al. | 2015 | NSCLC | 211 | OS | Yes | SUVmax, GTV | 3.0 | Fitted | OSEM | SBRT | T1-2N0M0 | 25.2 months | HR |
| Lee et al. | 2012 | NSCLC | 205 | OS | Yes | SUVmax | 13.0 | Fitted | Iterative | Neoadj. CRT, + surgery | IIIA | 1.6 years | HR |
| Nair et al. | 2014 | NSCLC | 163 | PFS, OS, LRFS, DMFS | Yes | SUVmax | 7.0 | Median | - | RT, SBRT | T1-2N0M0 | 16 months | KM |
| Nawara et al. | 2012 | NSCLC | 91 | OS | No | SUVmax, SUVmean | 7.0 | Median | Iterative | RT +/− induction CT | I-IIIB | - | KM |
| Pyka et al. | 2015 | NSCLC | 45 | DSS, OS | Yes | SUVmax, SUVmean, MTV, COV, entropy, coarseness, contrast, correlation | 11.2 (OS), 12.3 (DSS) | Fitted | OSEM | SBRT | T1-2N0M0 | 21.4 months | KM |
| Sasaki et al. | 2005 | NSCLC | 162 | OS, DFS | Yes | SUVmax | 5.0 | Fitted | Iterative | Surgery +/− RT or RT/CRT | I-IIIB | 17 months | HR |
| Shirai et al. | 2017 | NSCLC | 45 | LC, PFS, OS | No | SUVmax | 5.5 | Median | - | C-ion RT | I | 28.9 months | KM |
| Sugawara et al. | 1999 | NSCLC | 38 | OS | No | SUVlean | 8.72 | Median | Hanning filter | Surgery, CRT | I-IV | 26.5 months | KM |
| Takeda et al. | 2011 | NSCLC | 95 | LC | No | SUVmax | 6.0 | Fitted | DRAMA | SBRT | IA-IIIB | 16 months | KM |
| Takeda et al. | 2014 | NSCLC | 152 | OS, DFS. LC, RC, DMC, CSS | Yes | SUVmax | 3.35 (LC), 3.64 (RC), 2.47 (DMC, DFS), 2.55 (CSS, OS) | Fitted | RAMLA | SBRT | T1-2N0M0 | 25.3 months | HR |
| Takeda et al. | 2017 | NSCLC | 26 | LC, PFS, OS | No | SUV, MTV, TLG, entropy, dissimilarity, HILAE, zone percentage | 8.18 | Median | OSEM | SBRT | T1-2N0M0 | 36 months | KM |
| Ulger et al. | 2014 | NSCLC | 103 | OS, RFS, DFS | Yes | SUVmax | 10.7 | Median | - | 3D-CRT | IIIA-IIIB | 22.63 months | HR |
| Vansteenkiste et al. | 1999 | NSCLC | 125 | OS | Yes | SUVmax | 7.0 | Fitted | - | Surgery +/− induction CT, RT +/− induction CT | I-IIIB | 19 months (mean) | HR |
| Vesselle et al. | 2007 | NSCLC | 208 | OS, DFS | Yes | SUVmax | 7.0 | Fitted | Hanning filter | Surgery +/− neoadj. Or adjuvant therapy | I-IV | 37 months | HR |
| Vu et al. | 2013 | NSCLC | 50 | OS, RFS | No | SUVmax, TLG, MTV | 6.43 | Median | - | SBRT | I | 25.1 months | HR |
| Xiang et al. | 2012 | NSCLC | 84 | LRFS, DMFS, PFS, OS | Yes | SUVmax | 14.2 | Median | - | High dose proton + CT | III | 19.2 months | HR |
| Yilmaz et al. | 2018 | NSCLC | 67 | PFS, OS | Yes | SUVmax | 15.0 | Median | - | CRT | III | 20.7 months | HR |
* Performed multivariate analysis (MVA) in regards to the endpoints analyzed in this study: DFS and OS. Studies listed with author in italic are performed as prospective studies. Other studies are retrospective studies. NSCLC: non-small cell lung cancer, OS: overall survival, SUV: standardized uptake value, SUR: standardized uptake ratio, RT: radiotherapy, CRT: chemoradiotherapy, HR: hazard ratio, LC: local control, AID: average iodine density, SBRT: stereotactic body radiation therapy, DSS: disease-specific survival, OSEM: ordered-subset expectation maximum, KM: Kaplan-Meier, MTV: metabolic tumor volume, DFS: disease free survival, PFS: progression free survival, TLG: total lesion glycolysis, CT: chemotherapy, RFS: recurrence-free survival, CSS: cause-specific survival, RR: regional relapse, LR: local relapse, DM: distant metastasis, LFF: local failure free rate, PSF: point spread function, TOF: time of flight, RAMLA: row-action maximum-likelihood algorithm, GTV: gross tumor volume, LRFS: local recurrence-free survival, DMFS: distant metastasis free survival, COV: coefficient of variation, DRAMA: dynamic row-action expectation maximization algorithm, RC: regional control, DMC: distant metastasis control, HILAE: high-intensity large-area emphasis, and 3D-CRT: three-dimensional conformal radiotherapy.